Preclinical

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong, Thang Q. Le, Erminia Massarelli, Andrew E. Hendifar, Richard Tuli

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 46; DOI: 10.1186/s40425-018-0361-7
Evaluating in vivo efficacy – toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells
Inez Johanna, Trudy Straetemans, Sabine Heijhuurs, Tineke Aarts-Riemens, Håkan Norell, Laura Bongiovanni, Alain de Bruin, Zsolt Sebestyen, Jürgen Kuball

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 69; DOI: 10.1186/s40425-019-0558-4
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation
Ryan Michael Reyes, Yilun Deng, Deyi Zhang, Niannian Ji, Neelam Mukherjee, Karen Wheeler, Harshita B Gupta, Alvaro S Padron, Aravind Kancharla, Chenghao Zhang, Myrna Garcia, Anand V R Kornepati, Onur Boyman, Jose R Conejo-Garcia, Robert S Svatek, Tyler J Curiel

Journal for ImmunoTherapy of Cancer Apr 2021, 9 (4) e002051; DOI: 10.1136/jitc-2020-002051
Diacylglycerol kinase ζ limits IL-2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes
Javier Arranz-Nicolás, Miguel Martin-Salgado, Cristina Rodríguez-Rodríguez, Rosa Liébana, Maria C Moreno-Ortiz, Judith Leitner, Peter Steinberger, Antonia Ávila-Flores, Isabel Merida

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (2) e001521; DOI: 10.1136/jitc-2020-001521
CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy
Anne Y Lai, Jessica A Sorrentino, Konstantin H Dragnev, Jared M Weiss, Taofeek K Owonikoko, Julie A Rytlewski, Jill Hood, Zhao Yang, Rajesh K Malik, Jay C Strum, Patrick J Roberts

Journal for ImmunoTherapy of Cancer Oct 2020, 8 (2) e000847; DOI: 10.1136/jitc-2020-000847
Therapeutic efficacy and safety of a human fusion construct targeting the TWEAK receptor Fn14 and containing a modified granzyme B
Ana Alvarez de Cienfuegos, Lawrence H Cheung, Khalid A Mohamedali, Timothy G Whitsett, Jeffrey A Winkles, Walter N Hittelman, Michael G Rosenblum

Journal for ImmunoTherapy of Cancer Sep 2020, 8 (2) e001138; DOI: 10.1136/jitc-2020-001138

Main menu

Preclinical

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Preclinical

Pages